eMedicine Specialties > Pediatrics: General Medicine > Parasitology

Toxoplasmosis: Differential Diagnoses & Workup

Author: Hakan Leblebicioglu, MD, Chairman, Professor, Department of Infectious Diseases and Clinical Microbiology, Ondokuz Mayis University Medical School, Turkey
Coauthor(s): Murat Hökelek, MD, PhD, Technical Consultant of Parasitology Laboratory, Associate Professor, Department of Clinical Microbiology, Ondokuz Mayis University Medical School, Turkey; Itzhak Brook, MD, MSc, Professor, Department of Pediatrics, Georgetown University School of Medicine
Contributor Information and Disclosures

Updated: Oct 10, 2008

Differential Diagnoses

Catscratch Disease
Rubella
Cytomegalovirus Infection
Sarcoidosis
Herpes Simplex Virus Infection
Sepsis
Histoplasmosis
Syphilis
Leprosy
Tuberculosis
Listeria Infection
Tularemia
Lymph Node Disorders
Lymphocytic Choriomeningitis Virus
Mononucleosis and Epstein-Barr Virus Infection

Other Problems to Be Considered

Congenital toxoplasmosis - Encephalopathies, erythroblastosis fetalis, lymphocytic choriomeningitis virus infection
Toxoplasma encephalitis (TE) - Vasculitis, progressive multifocal leukoencephalopathy, malignancy, lymphocytic choriomeningitis virus infection

Workup

Laboratory Studies

  • Demonstration of T gondii in blood, body fluids, or tissues is evidence of toxoplasmosis infection.
  • Isolation by mouse inoculation of Toxoplasma from amniotic fluid or placental or fetal tissue is diagnostic of congenital infection.
  • Lymphocyte transformation in response to Toxoplasma antigens indicates previous infection in adults.
  • Detection of Toxoplasma antigens in blood or body fluids by means of enzyme-linked immunoassay (ELISA) indicates acute infection.
  • The Sabin-Feldman dye test is a sensitive and specific neutralization test. It measures immunoglobulin (Ig)G antibody and is the standard reference test for toxoplasmosis; however, it requires live T gondii and thus is not available in most laboratories. High titers suggest acute disease.
  • The indirect fluorescent antibody (IFA) test measures the same antibodies as the dye test. Titers parallel dye test titers. The IgM fluorescent antibody test can be used to detect IgM antibodies within the first week of infection, but titers fall within a few months.
  • The indirect hemagglutination test measures a different antibody than does the dye test. Titers tend to be higher and remain elevated longer.
  • The double-sandwich IgM ELISA is more sensitive and specific than other IgM detection tests.
  • The IgG avidity test may be able to discriminate acute from chronic infection better than alternative assays, such as assays that measure IgM antibodies. As is true for IgM antibody tests, the avidity test is most useful when performed early in gestation because a chronic pattern occurring late in pregnancy does not rule out the possibility that the acute infection may have occurred during the first months of gestation. A 2-fold rise in serum IgG obtained at 3-week intervals is diagnostic.
  • Performing polymerase chain reaction (PCR) on body fluids, including cerebrospinal fluid (CSF), amniotic fluid, bronchoalveolar lavage fluid, and blood, may be useful in establishing the diagnosis.5

Imaging Studies

  • Ultrasonography of the fetus to evaluate for evidence of congenital toxoplasmosis can be performed at 20-24 weeks' gestation.
  • CT scanning of the brain is useful in cerebral toxoplasmosis.
    • In 70-80% of immunodeficient patients with Toxoplasma encephalitis (TE), the CT scan reveals multiple bilateral ring-enhancing cerebral lesions.
    • Although multiple lesions are more common, finding a solitary lesion should not exclude TE.
    • The likelihood of TE is approximately 80% in patients with AIDS with detectable Toxoplasma IgG and multiple ring-enhancing lesions.
    • Lesions are characteristically hypodense and tend to occur at the corticomedullary junction, frequently involving the basal ganglia.
    • CT scanning frequently underestimates the number of lesions, although delayed imaging after a double dose of intravenous (IV) contrast material may improve the sensitivity of this imaging modality.
    • An enlarging hypodense lesion that does not enhance is a poor prognostic finding.
    • Improvement is seen in as many as 90% of patients with AIDS and TE after 2-3 weeks of treatment. Complete resolution lasts from 6 weeks to 6 months; peripheral lesions resolve more rapidly than deeper ones. Radiographic response tends to lag behind clinical response.
  • MRI is the preferred imaging modality to evaluate for lesions.
    • MRI has superior sensitivity, particularly if gadolinium is used for contrast. It can often depict lesions or more extensive disease not apparent on CT scan. Hence, MRI should be used as the initial imaging procedure when feasible and always follow CT demonstration of a single lesion.
    • MRI depicts TE lesions as high signal abnormalities on T2-weighted studies and reveals a rim of enhancement surrounding the edema on T1-weighted contrast-enhanced images.
    • Smaller lesions usually completely resolve on MRI studies within 3-5 weeks, but lesions with a mass effect tend to resolve more slowly and leave a small residual lesion.
  • Even characteristic lesions on CT or MRI are not pathognomonic of TE. The major differential diagnosis in patients with AIDS is CNS lymphoma, which appears with multiple enhancing lesions in 40% of cases.
  • To evaluate patients with AIDS and focal CNS lesions, various positron emission tomography and radionuclide scans have been used, generally with minimal benefit over the above modalities.

Other Tests

  • A skin test showing delayed hypersensitivity to Toxoplasma antigens may be a useful screening test.
  • Antibody levels in aqueous humor or CSF may reflect local antibody production and infection at these sites.
  • Perform an amniocentesis at 20-24 weeks' gestation in suspected cases of congenital disease.

Procedures

  • When single lesions are depicted on MRI, the probability of TE falls and that of lymphoma rises. Brain biopsy findings are generally required to obtain a definitive diagnosis.

Histologic Findings

  • The histopathology of toxoplasmosis varies with the immune status of the host.
    • In the healthy host with acquired toxoplasmosis, the characteristic histopathology of the lymph node is diagnostic, despite the relative paucity of organisms present. Typical findings include reactive follicular hyperplasia, irregular clusters of histiocytes encroaching on the margins of germinal centers, and focal distention of sinuses with monocytoid cells. Necrosis, granuloma formation, microabscesses, and vasculitis do not occur. At autopsy of normal hosts, tissue cysts are noted as incidental findings in skeletal muscle and myocardium, invoking little inflammatory response.
    • By contrast, in patients who are immunodeficient and in children with severe congenital toxoplasmosis, tachyzoite proliferation is accompanied by tissue necrosis and an intense, usually monocytic, inflammatory response. In patients with AIDS, toxoplasmosis typically produces brain abscesses that have a characteristic appearance. A central avascular area is surrounded by a region of necrosis and inflammatory cells that may also contain free and intracellular tachyzoites. Outside of the region of inflammation are cysts.
  • Demonstration of tachyzoites in a tissue specimen is required for definitive diagnosis of active infection. The presence of multiple cysts near an inflammatory lesion makes the diagnosis highly likely. Stains used to detect tachyzoites or cysts include hematoxylin and eosin, periodic acid-Schiff, and Gomori-methenamine silver. Immunoperoxidase and fluorescein-conjugated antibody stains can also be used. Wright-Giemsa staining of body fluid sediments of biopsy tissue touch preparations is a rapid and simple method for visualizing the organisms.

More on Toxoplasmosis

Overview: Toxoplasmosis
Differential Diagnoses & Workup: Toxoplasmosis
Treatment & Medication: Toxoplasmosis
Follow-up: Toxoplasmosis
Multimedia: Toxoplasmosis
References

References

  1. Hill DE, Chirukandoth S, Dubey JP. Biology and epidemiology of Toxoplasma gondii in man and animals. Anim Health Res Rev. Jun 2005;6(1):41-61. [Medline].

  2. Ferguson W, Mayne PD, Lennon B, Butler K, Cafferkey M. Susceptibility of pregnant women to toxoplasma infection--potential benefits for newborn screening. Ir Med J. Jul-Aug 2008;101(7):220-1. [Medline].

  3. Trikha I, Wig N. Management of toxoplasmosis in AIDS. Indian J Med Sci. 2001;55:87-98. [Medline].

  4. Jones JL, Lopez A, Wilson M, et al. Congenital toxoplasmosis: a review. Obstet Gynecol Surv. 2001;56:296-305. [Medline].

  5. Bonfioli AA, Orefice F. Toxoplasmosis. Semin Ophthalmol. Jul-Sep 2005;20(3):129-41. [Medline].

  6. Foulon W, Naessens A, Ho-Yen D. Prevention of congenital toxoplasmosis. J Perinat Med. 2000;28:337-45. [Medline].

  7. Beaman MH. Toxoplasmosis. In: Rakel, ed. Conn's Current Therapy. 53rd ed. Philadelphia, PA: WB Saunders; 2001:156-62.

  8. Boyer KM. Diagnostic testing for congenital toxoplasmosis. Pediatr Infect Dis J. 2001;20:59-60. [Medline].

  9. Darde ML. Toxoplasma gondii, "new" genotypes and virulence. Parasite. Sep 2008;15(3):366-71. [Medline].

  10. Gardner WG. Toxoplasmosis. In: Dambro MR, ed. Griffith's 5-Minute Clinical Consult. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:1090-1.

  11. McLeod R, Boyer K, Roizen N, et al. The child with congenital toxoplasmosis. Curr Clin Top Infect Dis. 2000;20:189-208. [Medline].

  12. Montoya JG, Rosso F. Diagnosis and management of toxoplasmosis. Clin Perinatol. Sep 2005;32(3):705-26. [Medline].

  13. Peyron F, Wallon M. Options for the pharmacotherapy of toxoplasmosis during pregnancy. Expert Opin Pharmacother. 2001;2:1269-74. [Medline].

  14. Pinon JM, Dumon H, Chemla C, et al. Strategy for diagnosis of congenital toxoplasmosis: evaluation of methods comparing mothers and newborns and standard methods for postnatal detection of immunoglobulin G, M, and A antibodies. J Clin Microbiol. 2001;39:2267-71. [Medline].

  15. Remington JS, Mc Leod R, Thulliez P. Toxoplasmosis. In: Remington JS and Klein JO,eds. Infectious Diseases of the Fetus and Newborn. 2001:205-346.

  16. Robert-Gangneux F. Contribution of new techniques for the diagnosis of congenital toxoplasmosis. Clin Lab. 2001;47:135-41. [Medline].

  17. Schwartzman JD. Toxoplasmosis. Curr Infect Dis Rep. 2001;3:85-89. [Medline].

  18. Tenter AM, Heckeroth AR, Weiss LM, et al. Toxoplasma gondii: from animals to humans. Int J Parasitol. 2000;30:1217-58. [Medline].

  19. Tierney LM Jr, McPhee SJ, Papadakis MA. Toxoplasmosis. In: Current Medical Diagnosis & Treatment. 40th ed. McGraw Hill; 2001:1444-7.

Further Reading

Keywords

toxoplasmosis, Toxoplasma gondii, congenital toxoplasmosis, congenital infection, bradyzoites, sporozoites, tachyzoites, chorioretinitis, Sabin-Feldman dye test, acquired immunodeficiency syndrome, AIDS, cerebral calcification, hydrocephalus, lymphadenopathy, myalgia, intrauterine growth retardation, jaundice, splenomegaly, nystagmus, papillitis

Contributor Information and Disclosures

Author

Hakan Leblebicioglu, MD, Chairman, Professor, Department of Infectious Diseases and Clinical Microbiology, Ondokuz Mayis University Medical School, Turkey
Hakan Leblebicioglu, MD is a member of the following medical societies: American Society for Microbiology
Disclosure: Nothing to disclose.

Coauthor(s)

Murat Hökelek, MD, PhD, Technical Consultant of Parasitology Laboratory, Associate Professor, Department of Clinical Microbiology, Ondokuz Mayis University Medical School, Turkey
Murat Hökelek, MD, PhD is a member of the following medical societies: Turkish Society for Parasitology
Disclosure: Nothing to disclose.

Itzhak Brook, MD, MSc, Professor, Department of Pediatrics, Georgetown University School of Medicine
Itzhak Brook, MD, MSc is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians-American Society of Internal Medicine, American Federation for Clinical Research, American Medical Association, American Society for Microbiology, Armed Forces Infectious Diseases Society, Association of Military Surgeons of the US, Infectious Diseases Society of America, International Immunocompromised Host Society, International Society for Infectious Diseases, Medical Society of the District of Columbia, New York Academy of Sciences, Pediatric Infectious Diseases Society, Society for Ear, Nose and Throat Advances in Children, Society for Experimental Biology and Medicine, Society for Pediatric Research, Southern Medical Association, and Surgical Infection Society
Disclosure: Nothing to disclose.

Medical Editor

Robert W Tolan Jr, MD, Chief, Division of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine
Robert W Tolan Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa, and Physicians for Social Responsibility
Disclosure: GlaxoSmithKline Honoraria Speaking and teaching; MedImmune Honoraria Consulting; MedImmune Honoraria Speaking and teaching; Merck Honoraria Speaking and teaching; Novartis Honoraria Speaking and teaching; sanofi pasteur Grant/research funds Unrestricted research grant; sanofi pasteur  Consulting; sanofi pasteur Honoraria Speaking and teaching; Tap Honoraria Speaking and teaching

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from broker recommendation; Avanir Pharma Stock Investment from broker recommendation

Managing Editor

Leslie L Barton, MD, Professor, Program Director, Department of Pediatrics, University of Arizona School of Medicine
Leslie L Barton, MD is a member of the following medical societies: American Academy of Pediatrics, Association of Pediatric Program Directors, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society
Disclosure: Nothing to disclose.

CME Editor

Daniel Rauch, MD, FAAP, Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine
Daniel Rauch, MD, FAAP is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Society of Hospital Medicine
Disclosure: Baxter Honoraria Consulting; Pfizer Honoraria Consulting

Chief Editor

Russell W Steele, MD, Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine
Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association
Disclosure: None None None

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.